David Lorente
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Lorente has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Juan Morote
Department of Surgery Universitat Autònoma de Barcelona Bellaterra Spain
14 shared publications - Enrique Trilla
Department of Surgery Universitat Autònoma de Barcelona Bellaterra Spain
10 shared publications - Lucas Regis
Department of Urology, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute (VHIR), 08025 Barcelona, Spain
10 shared publications - Ana Celma
Department of Urology, Hospital Univeritari Vall d´Hebron, Barcelona, Spain, Spain
9 shared publications J. Placer
Departamento de Urología, Hospital Universitari Vall d' Hebron, Universitat Autonoma de Barcelona, Barcelona, España
8 shared publicationsC. Salvador
Servicio de Urología, Hospital de la Vall d'Hebrón, Universidad Autónoma de Barcelona, Barcelona, España
7 shared publications
Latest Publications
- 29 May 2020
- Published by Wiley in Colorectal Disease
- Vol. 22 (11) , 1770-1771
Robotic right hemicolectomy and partial nephrectomy for synchronous malignancies – a video vignette
- 29 May 2020
- Published by Wiley in Colorectal Disease
- Vol. 22 (11) , 1770-1771
Robotic right hemicolectomy and partial nephrectomy for synchronous malignancies – a video vignette
- 1 May 2020
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 44 (4) , 245-250
Análisis de la expresión nuclear de pSer727-STAT3 como factor pronóstico en pacientes con carcinoma renal de células claras
- 1 May 2020
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 44 (4) , 245-250
Análisis de la expresión nuclear de pSer727-STAT3 como factor pronóstico en pacientes con carcinoma renal de células claras
- 1 April 2019
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 43 (3) , 137-142
La resonancia magnética preoperatoria predice la recuperación temprana de la continencia urinaria tras la prostatectomía radical robótica
- 1 April 2019
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 43 (3) , 137-142
La resonancia magnética preoperatoria predice la recuperación temprana de la continencia urinaria tras la prostatectomía radical robótica
- 1 April 2019
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 43 (3) , 118-123
Valor de la proteína STAT3 como factor pronóstico en el carcinoma renal de célula clara. Revisión sistemática
- 1 April 2019
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 43 (3) , 118-123
Valor de la proteína STAT3 como factor pronóstico en el carcinoma renal de célula clara. Revisión sistemática
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2192
Prostate capsule extension: Can we plan surgical treatment based on MRI findings? An analysis of predictive factors to better identify T3a before surgery
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2192
Prostate capsule extension: Can we plan surgical treatment based on MRI findings? An analysis of predictive factors to better identify T3a before surgery
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e293
Gleason pattern 4 or 5 at a positive surgical margin predicts early biochemical recurrence (<12 months) after robotic radical prostatectomy
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e293
Gleason pattern 4 or 5 at a positive surgical margin predicts early biochemical recurrence (<12 months) after robotic radical prostatectomy
- 2 January 2019
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 53 (1) , 21-25
The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?
Purpose: It remains unclear whether patients with prostate cancer suspicion and negative magnetic resonance imaging (M.R.I.) can safely obviate biopsy. The purpose of this study was to assess the clinical negative predictive value (N.P.V.) of M.R.I. in excluding prostate cancer. The secondary end-point was to compare N.P.V. to detect significant prostate cancer of M.R.I.The secondary end-point was to compare N.P.V. to detect significant prostate cancer in M.R.I. classified as P.I.-R.A.D.S.1 and as P.I.-R.A.D.S.2 Methods: From December 2012 to January 2017, 1128 M.R.I.s were performed consecutively due to prostate cancer clinical suspicion. The absence of suspicious and presence of low-risk areas were considered as negative M.R.I., P.I.-R.A.D.S.1 and 2. Biopsy results were compared according to P.I.-R.A.D.S. classification. The clinically significant disease was defined as International Society of Urological Pathology group higher than 1. Results: Two hundred and twenty-two (20%) M.R.I.s didn’t highlight targetable imaging suspicious areas, which were recorded as negative tests: 130 (59%) P.I.-R.A.D.S.1 and 92 (41%) P.I.-R.A.D.S.2. Detection of clinically significant prostate cancer in at least one biopsy core was higher in the P.I.-R.A.D.S.2 group, 9% (8/92) vs 3% (4/130), p = 0.047. The N.P.V. in biopsy-naïve men and P.I.-R.A.D.S.1 was 95% for significant disease, while in patients subjected to repeated biopsies and P.I.-R.A.D.S.1, the N.P.V. found was 99%. Those rates differ from the P.I.-R.A.D.S.2 group: N.P.V. in biopsy-naïve patients was 84%, and 95% in repeated biopsy. Conclusions: P.I.-R.A.D.S.2 shouldn’t be considered as a negative M.R.I. A biopsy cannot be routinely omitted in biopsy-naïve men with clinical suspicion of cancer and a low-suspicious area in M.R.I., giving the possibility of missing clinically significant tumors.
- 2 January 2019
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 53 (1) , 21-25
The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?
Purpose: It remains unclear whether patients with prostate cancer suspicion and negative magnetic resonance imaging (M.R.I.) can safely obviate biopsy. The purpose of this study was to assess the clinical negative predictive value (N.P.V.) of M.R.I. in excluding prostate cancer. The secondary end-point was to compare N.P.V. to detect significant prostate cancer of M.R.I.The secondary end-point was to compare N.P.V. to detect significant prostate cancer in M.R.I. classified as P.I.-R.A.D.S.1 and as P.I.-R.A.D.S.2 Methods: From December 2012 to January 2017, 1128 M.R.I.s were performed consecutively due to prostate cancer clinical suspicion. The absence of suspicious and presence of low-risk areas were considered as negative M.R.I., P.I.-R.A.D.S.1 and 2. Biopsy results were compared according to P.I.-R.A.D.S. classification. The clinically significant disease was defined as International Society of Urological Pathology group higher than 1. Results: Two hundred and twenty-two (20%) M.R.I.s didn’t highlight targetable imaging suspicious areas, which were recorded as negative tests: 130 (59%) P.I.-R.A.D.S.1 and 92 (41%) P.I.-R.A.D.S.2. Detection of clinically significant prostate cancer in at least one biopsy core was higher in the P.I.-R.A.D.S.2 group, 9% (8/92) vs 3% (4/130), p = 0.047. The N.P.V. in biopsy-naïve men and P.I.-R.A.D.S.1 was 95% for significant disease, while in patients subjected to repeated biopsies and P.I.-R.A.D.S.1, the N.P.V. found was 99%. Those rates differ from the P.I.-R.A.D.S.2 group: N.P.V. in biopsy-naïve patients was 84%, and 95% in repeated biopsy. Conclusions: P.I.-R.A.D.S.2 shouldn’t be considered as a negative M.R.I. A biopsy cannot be routinely omitted in biopsy-naïve men with clinical suspicion of cancer and a low-suspicious area in M.R.I., giving the possibility of missing clinically significant tumors.
- Open Access
- 1 January 2019
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 72 (2) , 92-99
Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation
Introduction An association between the R.E.N.A.L. nephrometry score (RNS) and clinical outcomes in patients with a small renal mass (SRM) has been proposed. We analyzed clinical outcomes according to the RNS in patients with a SRM treated with percutaneous contrast enhanced ultrasound (CEUS) radiofrequency ablation (RFA). Material and methods Patients with a SRM, who underwent RFA between January 2005 and March 2015, were retrospectively identified. The association between RNS and clinical outcomes was evaluated using parametric and non-parametric analysis. Results We analyzed 163 SRMs in 149 consecutive patients. The mean age was 71.7 years. Mean followup time was 33.3 months +/- 20.6 (2-102). The mean RNS was 5.6 +/- 1.52 (4-11). A total of 121 (74.2%) cases were of low complexity and 42 (25.8%) were medium complexity. We identified 11 cases of tumor persistence (6.7%). The mean RNS was 5.58 in the cases with no persistence and 5.73 in the cases with persistence (p = 0.788). We identified 15 (9.2%) cases of recurrence. The mean RNS was 5.57 +/- 0.1 (4-11) in the cases without recurrence and 5.73 +/- 0.4 (4-9) in recurrence cases (p = 0.804). Of the 76 biopsy proven RCC cases, 8 (10.5%) cases of recurrence were observed, 5 in the low complexity group and 3 in the medium complexity group (p = 0.690). A total of 9 (5.5%) cases of complications were observed, with 5 (4.3%) in the low complexity group and 4 cases in the medium complexity group (p = 0.23). The mean length of stay was 1.5 days with a significant difference between low and medium complexity groups (1.3 vs. 2.1 days, p = 0.02). The mean difference between preoperative eGFR and estimated eGFRat 12 months was-3.08 mL/min +/- 13.3 (-49.4-34.1) and was significant (p = 0.008).However, this variation did not show significant differences between the low and medium complexity groups (p = 0.936). Allcause mortality was 11.7%, 14 cases (11.6%) in the low complexity group and 5 (11.9%) in the medium complexity group (p = 1.0). No cases of renal cell carcinoma (RCC) specific mortality were identified. Conclusions The RNS was not associated with tumor persistence, recurrence, cancer specific mortality, complications or renal function 12 months after the first treatment, showing significant difference only in length of hospital stay between low and medium complexity groups.
- 1 January 2019
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 72 (2) , 92-99
Open AccessAssociation among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation
Introduction An association between the R.E.N.A.L. nephrometry score (RNS) and clinical outcomes in patients with a small renal mass (SRM) has been proposed. We analyzed clinical outcomes according to the RNS in patients with a SRM treated with percutaneous contrast enhanced ultrasound (CEUS) radiofrequency ablation (RFA). Material and methods Patients with a SRM, who underwent RFA between January 2005 and March 2015, were retrospectively identified. The association between RNS and clinical outcomes was evaluated using parametric and non-parametric analysis. Results We analyzed 163 SRMs in 149 consecutive patients. The mean age was 71.7 years. Mean followup time was 33.3 months +/- 20.6 (2-102). The mean RNS was 5.6 +/- 1.52 (4-11). A total of 121 (74.2%) cases were of low complexity and 42 (25.8%) were medium complexity. We identified 11 cases of tumor persistence (6.7%). The mean RNS was 5.58 in the cases with no persistence and 5.73 in the cases with persistence (p = 0.788). We identified 15 (9.2%) cases of recurrence. The mean RNS was 5.57 +/- 0.1 (4-11) in the cases without recurrence and 5.73 +/- 0.4 (4-9) in recurrence cases (p = 0.804). Of the 76 biopsy proven RCC cases, 8 (10.5%) cases of recurrence were observed, 5 in the low complexity group and 3 in the medium complexity group (p = 0.690). A total of 9 (5.5%) cases of complications were observed, with 5 (4.3%) in the low complexity group and 4 cases in the medium complexity group (p = 0.23). The mean length of stay was 1.5 days with a significant difference between low and medium complexity groups (1.3 vs. 2.1 days, p = 0.02). The mean difference between preoperative eGFR and estimated eGFRat 12 months was-3.08 mL/min +/- 13.3 (-49.4-34.1) and was significant (p = 0.008).However, this variation did not show significant differences between the low and medium complexity groups (p = 0.936). Allcause mortality was 11.7%, 14 cases (11.6%) in the low complexity group and 5 (11.9%) in the medium complexity group (p = 1.0). No cases of renal cell carcinoma (RCC) specific mortality were identified. Conclusions The RNS was not associated with tumor persistence, recurrence, cancer specific mortality, complications or renal function 12 months after the first treatment, showing significant difference only in length of hospital stay between low and medium complexity groups.
- 1 May 2018
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 42 (4) , 218-226
Systematic review of kidney transplantation functional predictors
- 1 May 2018
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 42 (4) , 218-226
Systematic review of kidney transplantation functional predictors